Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,595.00
Bid: 1,595.00
Ask: 1,595.50
Change: -23.00 (-1.42%)
Spread: 0.50 (0.031%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday preview: GlaxoSmithKline to report difficult quarter, analysts say

Tue, 05th Feb 2013 15:01

Healthcare giant GlaxoSmithKline is expected to report 'another difficult quarter' when the company unveils its latest results Wednesday, according to analysts.The pharmaceuticals group will post its full-year and fourth quarter financials, a day after announcing it increased its stake in its Indian consumer healthcare subsidiary by investing more than half a billion pounds in the unit. "We expect another difficult quarter as the company experiences some tough [year on year] comparisons [Advair & Cervarix], EU austerity and a forex headwind," analysts at Credit Suisse said.The broker expects a 3.0% fall in sales and 4.0% decline in earnings per share (EPS) in the fourth quarter. About £50m of incremental vaccine tenders will offset some of the negatives in the quarter but many of the headwinds look set to continue into early 2013 including its products Cervarix, Vesicare, Lamictal XR, it added.Credit Suisse said a solid dividend yield of circa 5.0% will remain an attraction for the stock along with a free cash flow generation of circa £5.0bn per annum. "We forecast an ongoing £2.0bn per annum share buyback programme to double operational EPS growth of 3-6% [2012-16 compound annual growth rate]. However, we see limited opportunity for this to improve in the near term, in the absence of significant top line growth."Shares were down 0.91% to €5.57 at 16:02.INTERIMS Hargreaves Lansdown INTERIM DIVIDEND PAYMENT DATE Ashtead Group, Halma, Vodafone Group INTERIM EX-DIVIDEND DATE Cohort, Daejan Holdings, Ingenious Entertainment VCT 1, Ingenious Entertainment VCT 1 'C' Shares, Ingenious Entertainment VCT 1 'D' Shares, Ingenious Entertainment VCT 1 E Shares, Ingenious Entertainment VCT 1 F Shares, Ingenious Entertainment VCT 2, Ingenious Entertainment VCT 2 'C' Shares, Ingenious Entertainment VCT 2 'D' Shares, Ingenious Entertainment VCT 2 F Shares, Mattioli Woods, Penna Consulting, Puma High Income VCT , Puma Vct 8, Puma Vct VII, Stagecoach Group, Tricorn Group QUARTERLY EX-DIVIDEND DATE IBM Corp., JPMorgan Claverhouse Inv Trust, Unilever INTERNATIONAL ECONOMIC ANNOUNCEMENTS PMI Construction (GER) (08:55) Q3 Canaccord Financial Inc. Q4 GlaxoSmithKline, Virgin Media Inc., Wolfson Microelectronics FINALS GlaxoSmithKline, New Europe Property Investments, Virgin Media Inc., Wolfson Microelectronics IMSS Grainger SPECIAL EX-DIVIDEND PAYMENT DATE Rensburg AIM VCT AGMS Blackrock Income And Growth Investment Trust, LED International Holdings Ltd (DI), Redhall Group UK ECONOMIC ANNOUNCEMENTS BRC Shop Price Index (00:01) New Car Registrations (09:30) FINAL DIVIDEND PAYMENT DATE Edinburgh Worldwide Inv Trust FINAL EX-DIVIDEND DATE Noble Investments (UK), Victrex Thursday February 07 INTERIMS Mcbride INTERIM DIVIDEND PAYMENT DATE FirstGroup INTERNATIONAL ECONOMIC ANNOUNCEMENTS Consumer Credit (US) (20:00) ECB Interest Rate (EU) (12:45) Industrial Production (GER) (11:00) Productivity (US) (13:30) Q4 Smith & Nephew FINALS Beazley, Smith & Nephew IMSS Avon Rubber, Supergroup, Vodafone Group EGMS Hotel Corporation (The) AGMS Avon Rubber, BlackRock New Energy Inv Trust, Compass Group, Downing Absolute Income VCT 1, Downing Absolute Income VCT 1 'C' Shares , Downing Income Vct, Downing Income Vct 4, Paragon Group Of Companies, Thomas Cook Group, TUI Travel, Unicorn AIM VCT TRADING ANNOUNCEMENTS Bellway UK ECONOMIC ANNOUNCEMENTS Balance of Trade (09:30) BoE Interest Rate Decision (12:00) FINAL DIVIDEND PAYMENT DATE Cardiff Property, JPMorgan Asian Inv Trust Q1 TUI Travel, TUI Travel
More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.